U.S.A., Dec. 3, 2020 /PRNewswire/ — Prior authorizations were the most costly and time-consuming transactions for providers in 2019 and are among the top reasons patient care is delayed. As cash-strapped hospitals and health systems strive to meet patient, payer and provider needs, the demand for AI technologies to increase efficiency and improve the patient experience has become critical. To help improve patient access to care and remedy the $31 billion prior authorization challenge, Olive announced the acquisition of Verata Health to solve prior authorizations for providers and payers via artificial intelligence as a combined solution under the Olive name.
Verata is a leading healthcare AI company, enabling Frictionless Prior Authorization® for providers and payers. Seamlessly connected to the nation’s top electronic health record (EHR) systems, Verata’s AI technology automatically initiates prior authorizations, retrieves payer rules, and helps identify and submit clinical documentation from the EHR. When payers leverage its AI platform, Verata enables point-of-care authorizations for providers and patients, dramatically accelerating access to care.
Olive and Verata’s combined prior authorization solution streamlines the process for providers, patients and payers by reducing write-offs by over 40% and cutting turnaround time for prior authorizations by up to 80%.
By integrating Verata’s solution, Olive is able to provide customers with a true end-to-end prior authorization solution. The solution starts with determining if an authorization is required, includes touchless submission of the prior authorization request, ends with automating denied claim appeals and grants hospitals a 360 degree view of their authorization performance. This means patients not only get the care they need faster, but also eliminates confusing bills patients receive post-service stating their claim has been denied by their insurance.
“Caring for patients at Mayo Clinic was life-changing,” said Dr. Jeremy Friese, CEO of Verata and former Mayo physician executive. “We started Verata to have an impact on patients and providers across the country. Combining our AI solution with Olive’s creates the leading platform to solve prior authorization on ‘both ends of the fax machine’ at providers and payers to drive impact for millions of patients.”
More than 60 Verata employees will join the Olive team following the acquisition, bringing Olive’s total employee count to approximately 500. Olive’s senior executive team will continue to grow as well:
“A broken healthcare system is one of the biggest challenges humanity faces today and prior authorization issues in particular are costing our nation billions of dollars. After partnering with Verata earlier this year, we saw incredible potential for Verata’s technology to reduce the amount of time and money spent on prior authorizations, and to eliminate delays in patient care,” said Sean Lane, CEO of Olive. “This acquisition allows Olive to accelerate innovation in areas where we can drive the biggest impact, and further expands our solutions to providers and payers seeking to transform healthcare.”
The acquisition follows Olive’s recent $225.5 million financing round to bolster the company’s R&D war chest and drive the growth of Olive’s AI workforce for providers and payers. Recently, Olive also announced Olive Helps: a new AI platform that delivers targeted information to healthcare workers to enable better, faster results while reducing the time spent on administrative tasks. With Olive’s recent momentum, Verata’s suite of AI tools will deepen Olive’s impact as it automates the $31 billion problem of prior authorizations in healthcare.
For more information about Olive, visit www.oliveai.com.
About Olive
Olive’s AI workforce is built to fix our broken healthcare system by addressing healthcare’s most burdensome issues — delivering hospitals and health systems and payers increased revenue, reduced costs, and increased capacity. People feel lost in the system today and healthcare employees are essentially working in the dark due to outdated technology that creates a lack of shared knowledge and siloed data. Olive is designed to drive connections, shining a new light on the broken healthcare processes that stand between providers delivering patient care and payers. She uses AI to reveal life-changing insights that make healthcare more efficient, affordable and effective. Olive’s vision is to unleash a trillion dollars of hidden potential within healthcare by connecting its disconnected systems. Olive is improving healthcare operations today, so everyone can benefit from a healthier industry tomorrow.
About Verata Health
Verata Health empowers hospitals, health systems and payers to take control of one of the biggest and most challenging problems in healthcare — prior authorization. A physician-led company trusted by customers across the country, Verata’s artificial intelligence platform is obsoleting the fax machine with Frictionless Prior Authorization®. Supporting both simple and clinically complex prior authorizations, Verata Health helps both providers and payers increase revenue, reduce administrative burden and accelerate patient access. Verata Health’s investors include BlueCross BlueShield Venture Partners, LRVHealth, CapitalFour, 3M and Bessemer Venture Partners. TripleTree, LLC served as the exclusive financial advisor to Verata Health for this transaction.
To learn more about Verata Health, visit www.veratahealth.com.
Media Contact:
Rachel Forsyth
oliveai@finnpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/olive-acquires-verata-health-to-accelerate-artificial-intelligence-technology-for-healthcare-providers-and-payers-301185294.html
SOURCE Olive
Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024…
Slovenia, Croatia, Turkey, and Greece Drive EHR Adoption in the Balkans, Setting New Standards in…
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…